Health care innovations have the potential to save lives, but not every advancement in this field has the necessary evidence to ensure it truly benefits patients. In the realm of restricted markets such as cannabis, stem cells, and cryptocurrencies, the barriers to innovation are notably higher.
In the case of cannabis, researchers face significant challenges due to high costs, limited access to essential resources, and stringent regulations. This creates a complex dynamic between regulatory limitations and the pursuit of research and innovation.
The federal classification of cannabis as having “no accepted medical use” contrasts sharply with its legalization for medical or recreational use in many states. Interestingly, the Department of Health and Human Services holds a patent related to cannabis for potential medical applications.
Research on cannabis spans various forms, including clinical trials focusing on treatment effects, user impacts, and abuse factors. In parallel, patents are being filed for a diverse array of purposes, including chemical formulations and consumer products like edibles and vaporizers.
James MacDonald/Bloomberg
Cannabis’ evolving legality in the US
Cannabis, known for its chemical compounds called cannabinoids, has psychoactive and non-psychoactive components. THC is known for its mind-altering effects, while CBD is used for anxiety and pain relief. Despite its varied uses, there’s insufficient evidence supporting its effectiveness for medical conditions.
Cannabis remains a Schedule I drug under U.S. federal law, a classification indicating high abuse potential and no accepted medical use. This status imposes significant hurdles for researchers seeking to study cannabis, necessitating approvals from both the FDA and DEA and restricting research to federally sanctioned cannabis varieties.
Efforts are ongoing to relax these regulations as more states legalize cannabis to varying extents. California pioneered medical cannabis laws in 1996, and as of June 2025, 40 states have followed suit. Additionally, recreational cannabis is legal in 24 states as of January 2026.
This evolving legal framework allows for reduced research costs in states with permissive laws, despite federal restrictions. For instance, researchers at Washington State University conducted studies by having participants purchase cannabis from legal dispensaries.
State legalization and cannabis innovation
Our study analyzes the impact of state legalization on cannabis-related innovation using datasets on clinical trials and patent applications. We categorized innovations based on medical treatments, usage, abuse, and consumer products.
Our findings indicate that recreational cannabis legalization boosts patent filings, primarily in commercial areas such as cultivation equipment and consumer products, rather than health-focused research. We also identified public health concerns associated with these innovations.
AP Photo/Seth Wenig
Legalization has not significantly increased clinical trials, highlighting persistent barriers like restricted access to research-grade cannabis and funding challenges. As cannabis culture is celebrated annually on 420, discussions continue around its legal status and public health implications.
Efforts by the Biden and second Trump administrations to reclassify cannabis could shift its status, potentially increasing research opportunities. Addressing this gap between research and product innovation is crucial for public health, as demonstrated by past incidents involving unregulated cannabis products.
